Key Highlights
- Reginald Seeto, MBBS, appointed as CEO and President of Scipher Medicine.
- Scipher’s SpectraTM platform powers advancements in autoimmune diagnostics and biopharmaceuticals.
- PrismRA®, a key diagnostic tool for rheumatoid arthritis, recently secured MolDx approval.
Source: Business Wire
Notable Quotes
- “Scipher’s mission to revolutionize precision immunology through its innovative data platform is truly groundbreaking. I look forward to leveraging my experience to contribute to the company’s continued success.” – Reginald Seeto, Chief Executive Officer and President at Scipher Medicine
- “Reg has an established leadership track record in building both products and companies by setting bold strategies that can be delivered through high performing teams.” – Samir Kaul, Managing Director at Khosla Ventures
- “I am honored to be appointed Chair of the Audit Committee at Scipher. Scipher’s mission to revolutionize precision immunology through its innovative data platform is truly groundbreaking.” – Glenn Muir, Independent Director and Chair of the Audit Committee at Scipher Medicine
SoHC's Take
The strategic appointments of Reginald Seeto as CEO and Glenn Muir as Chair of the Audit Committee at Scipher Medicine mark significant steps toward enhancing the company’s impact in the precision immunology space. Dr. Seeto’s extensive background across diagnostic and therapeutic sectors, combined with Mr. Muir’s financial acumen and governance expertise, positions Scipher well for ambitious growth and innovation. This leadership reinforcement supports Scipher’s mission to tailor immunological treatments through data-driven insights, fostering more effective healthcare solutions for patients with autoimmune diseases.
